in ,

European Council President Michel warns pharmaceutical companies due to vaccine delivery delays

EU Council President Michel said that they plan to use the legal instruments at their disposal to ensure that pharmaceutical companies fulfill their vaccine contracts.

Charles Michel, President of the European Union (EU) Council, made evaluations on Europe 1 radio about the delays in the supply of new type of coronavirus (Covid-19) vaccine in Europe.

After the Pfizer / BioNTech company announced that vaccine deliveries would be delayed for a few weeks, Michel reminded that EU member states took a strict attitude and corrected this situation, “We hit our fist on the table and then we saw the delays decrease.” he spoke.

“We plan to use the legal tools at our disposal to enable pharmaceutical companies to fulfill their vaccine contracts.” used the expression.

Stating that companies are aware of the need to establish new production chains related to vaccines and that there may be difficulties in the supply of sufficient raw materials, Michel pointed out that pharmaceutical companies should provide “transparent” information about the delays in vaccine shipment.

Delays in vaccine delivery
After the pharmaceutical company Pfizer announced last week that it would temporarily reduce the delivery of vaccine to Europe due to production, it was reported that there may be delays in the delivery of the vaccine developed by Oxford-AstraZeneca, which has not yet received approval from the European Medicines Agency (EMA).

The vaccines developed by BioNTech and Pfizer and Moderna, which have been approved in the EU so far, have been applied to the public since December 2020.

EU approval for the vaccine developed by Oxford-AstraZeneca is expected next week.

The EU Commission has reached a position to receive approximately 2.3 billion doses with 6 contracts made on behalf of member countries with companies that develop vaccines to date. The EU has signed contracts to purchase 600 million doses of vaccine with BioNTech-Pfizer, 400 million doses with AstraZeneca, 300 million with Sanofi-GSK, 400 million with Johnson and Johnson, 405 million doses with CureVac and 160 million with Moderna, including options.

However, criticism is made that vaccination is slow in EU countries.

The EU Commission set a target this week to vaccinate 70 percent of the adult population in member countries by 1 June. As a result of delays in vaccine deliveries, the possibility of not reaching the target increases.

Written by Maraaz

Casualties and cases increased due to Covid-19 in Arab countries

Israeli newspaper: the US will install its air defense systems from Israel at its bases in the Gulf